Charles River Labs Presents Preliminary 2025 Financial Outlook at J.P. Morgan Conference

Details

announced that it will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will cover the Company's preliminary 2025 financial outlook and recent business trends, including stable demand in the Discovery and Safety Assessment (DSA) Segment and challenges in the CDMO business. Charles River expects organic revenue to decline similarly to 2024 levels, with several headwinds impacting revenue growth in 2025. The Company also expects non-GAAP operating margin to be modestly below the 2024 level.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.